Sevirumab
Sevirumab
Sevirumab (pronunciation: /sɛvɪˈruːmæb/) is a monoclonal antibody designed for the treatment of various diseases.
Etymology
The term "Sevirumab" is derived from the International Nonproprietary Names (INN), where 'sevi-' is a prefix used for monoclonal antibodies, and '-mab' is a suffix for monoclonal antibodies.
Definition
Sevirumab is a type of monoclonal antibody that is used in the treatment of various diseases. Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell, given that 'mono-' is a prefix meaning 'one', these are antibodies derived from a single cellular lineage. They are used in many forms of therapy because they can be designed to specifically bind to substances in the body, including cancer cells.
Usage
The usage of Sevirumab is still under research and development. It is being studied for its potential use in the treatment of various diseases, including cancer, autoimmune diseases, and infectious diseases.
Related Terms
External links
- Medical encyclopedia article on Sevirumab
- Wikipedia's article - Sevirumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski